Last updated on December 2019

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza Study)

Brief description of study

The purpose of Part A is to determine whether sutimlimab administration results in a greater than or equal to (>=)1.5 gram per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants with primary cold agglutinin disease (CAD) without a recent history of blood transfusion. The purpose of Part B is to evaluate the long-term safety and tolerability of sutimlimab in participants with primary CAD.

Clinical Study Identifier: NCT03347422

Find a site near you

Start Over

Cleveland Clinic

Cleveland, OH United States
  Connect »

East Carolina University

Greenville, NC United States
  Connect »

Montefiore Medical Center

New York, NY United States
  Connect »

ZNA Stuivenberg

Antwerpen, Belgium
  Connect »

USC/Keck School of Medicine

Los Angeles, CA United States
  Connect »

Cleveland Clinic Florida

Weston, FL United States
  Connect »

UW Hospitals and Clinics

Madison, WI United States
  Connect »

CHU d'Angers

Angers Cedex 9, France
  Connect »

Perth Blood Institute

West Perth, Australia
  Connect »